Cite
HARVARD Citation
Peng, G. et al. (2022). A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. Therapeutic advances in hematology. p. . [Online].